Literature DB >> 17360534

Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease.

Stephanie J Leuenroth1, Dayne Okuhara, Joseph D Shotwell, Glen S Markowitz, Zhiheng Yu, Stefan Somlo, Craig M Crews.   

Abstract

During kidney organogenesis, tubular epithelial cells proliferate until a functional tubule is formed as sensed by cilia bending in response to fluid flow. This flow-induced ciliary mechanosensation opens the calcium (Ca(2+)) channel polycystin-2 (PC2), resulting in a calcium flux-mediated cell cycle arrest. Loss or mutation of either PC2 or its regulatory protein polycystin-1 (PC1) results in autosomal dominant polycystic kidney disease (ADPKD), characterized by cyst formation and growth and often leading to renal failure and death. Here we show that triptolide, the active diterpene in the traditional Chinese medicine Lei Gong Teng, induces Ca(2+) release by a PC2-dependent mechanism. Furthermore, in a murine model of ADPKD, triptolide arrests cellular proliferation and attenuates overall cyst formation by restoring Ca(2+) signaling in these cells. We anticipate that small molecule induction of PC2-dependent calcium release is likely to be a valid therapeutic strategy for ADPKD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360534      PMCID: PMC1838612          DOI: 10.1073/pnas.0700499104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells.

Authors:  K Y Lee; W Chang; D Qiu; P N Kao; G D Rosen
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

2.  Organic cation permeation through the channel formed by polycystin-2.

Authors:  Georgia I Anyatonwu; Barbara E Ehrlich
Journal:  J Biol Chem       Date:  2005-06-16       Impact factor: 5.157

3.  Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii.

Authors:  S M Kupchan; W A Court; R G Dailey; C J Gilmore; R F Bryan
Journal:  J Am Chem Soc       Date:  1972-10-04       Impact factor: 15.419

4.  The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.

Authors:  Jonathan M Shillingford; Noel S Murcia; Claire H Larson; Seng Hui Low; Ryan Hedgepeth; Nicole Brown; Chris A Flask; Andrew C Novick; David A Goldfarb; Albrecht Kramer-Zucker; Gerd Walz; Klaus B Piontek; Gregory G Germino; Thomas Weimbs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

5.  Identification and characterization of polycystin-2, the PKD2 gene product.

Authors:  Y Cai; Y Maeda; A Cedzich; V E Torres; G Wu; T Hayashi; T Mochizuki; J H Park; R Witzgall; S Somlo
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

6.  Studies on calcium dependence reveal multiple modes of action for triptolide.

Authors:  Stephanie J Leuenroth; Craig M Crews
Journal:  Chem Biol       Date:  2005-12

7.  Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.

Authors:  Yunxia Tao; Jun Kim; Robert W Schrier; Charles L Edelstein
Journal:  J Am Soc Nephrol       Date:  2004-11-24       Impact factor: 10.121

8.  Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.

Authors:  Tamio Yamaguchi; Scott J Hempson; Gail A Reif; Anne-Marie Hedge; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2005-11-30       Impact factor: 10.121

9.  A polycystic kidney-disease gene homologue required for male mating behaviour in C. elegans.

Authors:  M M Barr; P W Sternberg
Journal:  Nature       Date:  1999-09-23       Impact factor: 49.962

10.  Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells.

Authors:  Bing Z Carter; Duncan H Mak; Wendy D Schober; Teresa McQueen; David Harris; Zeev Estrov; Randall L Evans; Michael Andreeff
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

View more
  86 in total

1.  XPB, a subunit of TFIIH, is a target of the natural product triptolide.

Authors:  Denis V Titov; Benjamin Gilman; Qing-Li He; Shridhar Bhat; Woon-Kai Low; Yongjun Dang; Michael Smeaton; Arnold L Demain; Paul S Miller; Jennifer F Kugel; James A Goodrich; Jun O Liu
Journal:  Nat Chem Biol       Date:  2011-01-30       Impact factor: 15.040

Review 2.  The role of targeted chemical proteomics in pharmacology.

Authors:  Chris W Sutton
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.

Authors:  Zhiyan Xiao; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-09-11       Impact factor: 12.944

Review 4.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 5.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

6.  Phosphoinositide 3-Kinase-C2α Regulates Polycystin-2 Ciliary Entry and Protects against Kidney Cyst Formation.

Authors:  Irene Franco; Jean Piero Margaria; Maria Chiara De Santis; Andrea Ranghino; Daniel Monteyne; Marco Chiaravalli; Monika Pema; Carlo Cosimo Campa; Edoardo Ratto; Federico Gulluni; David Perez-Morga; Stefan Somlo; Giorgio R Merlo; Alessandra Boletta; Emilio Hirsch
Journal:  J Am Soc Nephrol       Date:  2015-08-13       Impact factor: 10.121

Review 7.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 8.  Transient receptor potential (TRP) channels: a clinical perspective.

Authors:  Yosuke Kaneko; Arpad Szallasi
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 9.  Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.

Authors:  Takamitsu Saigusa; P Darwin Bell
Journal:  Physiology (Bethesda)       Date:  2015-05

10.  Triptolide protects podocytes from TGF-β-induced injury by preventing miR-30 downregulation.

Authors:  Qianqian Yang; Mengjie Sun; Ying Chen; Yuqiu Lu; Yuting Ye; Hui Song; Xiaodong Xu; Shaolin Shi; Jinquan Wang
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.